DaVita Inc. (DVA) EV/EBIT Ratio: 12.94x
Is DaVita Inc.’s EV/EBIT ratio high or low?
DaVita Inc.'s EV/EBIT ratio of 12.94x is in line with its 5-year average of 13.13x, around the middle of its 5-year range (10.44x–16.87x).
As of Monday, June 15, 2026. 9.75% above its 12-month average of 11.79x.
DVA EV/EBIT Ratio Chart
DVA Average EV/EBIT Ratio Chart
DVA Current vs Average EV/EBIT Ratio Chart
DVA EV/EBIT Ratio Metrics
EV/EBIT RATIO
12.94x
EV/EBIT RATIO AVG TTM
11.79x
EV/EBIT RATIO AVG 3Y
13.02x
EV/EBIT RATIO AVG 5Y
13.12x
EV/EBIT RATIO AVG 10Y
13.08x
EV/EBIT RATIO AVG 15Y
13.10x
EV/EBIT RATIO AVG 20Y
12.70x
CURRENT VS TTM AVG
+9.75%
CURRENT VS 3Y AVG
-0.58%
CURRENT VS 5Y AVG
-1.35%
CURRENT VS 10Y AVG
-1.08%
CURRENT VS 15Y AVG
-1.23%
CURRENT VS 20Y AVG
+1.88%
DVA Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DaVita Inc. (DVA) | $13.40B | 12.94x | 11.79x | 13.02x | 13.12x |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 31.25x | 23.67x | 31.83x | 35.66x |
| Solventum Corporation (SOLV)vs › | $13.66B | 8.70x | 20.82x | 17.36x | 17.36x |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 19.57x | 19.29x | 26.44x | 31.41x |
| Baxter International Inc. (BAX)vs › | $10.77B | N/A | 442.63x | 243.35x | 134.31x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | N/A | 25.59x | 34.39x | 25.01x |
| Hologic, Inc. (HOLX)vs › | $16.97B | 24.28x | 22.66x | 24.05x | 18.32x |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | 25.40x | 62.63x | 38.51x | 35.13x |
| Tempus AI, Inc. (TEM)vs › | $8.35B | N/A | -27.13x | -28.45x | -29.28x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 35.82x | 38.08x | 32.83x | 33.28x |
DaVita Inc. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DaVita Inc. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for DaVita Inc. (DVA)?
- The EV/EBIT ratio for DVA stock is 12.94x.
- Is DaVita Inc.'s EV/EBIT ratio high or low?
- DaVita Inc.'s EV/EBIT ratio of 12.94x is in line with its 5-year average of 13.13x, around the middle of its 5-year range (10.44x–16.87x).
- What is the TTM average EV/EBIT ratio for DaVita Inc. (DVA)?
- The TTM average EV/EBIT ratio for DVA stock is 11.79x.
- What is the 3Y average EV/EBIT ratio for DaVita Inc. (DVA)?
- The 3Y average EV/EBIT ratio for DVA stock is 13.02x.
- What is the 5Y average EV/EBIT ratio for DaVita Inc. (DVA)?
- The 5Y average EV/EBIT ratio for DVA stock is 13.12x.
- What is the 10Y average EV/EBIT ratio for DaVita Inc. (DVA)?
- The 10Y average EV/EBIT ratio for DVA stock is 13.08x.
- What is the 15Y average EV/EBIT ratio for DaVita Inc. (DVA)?
- The 15Y average EV/EBIT ratio for DVA stock is 13.10x.
- What is the 20Y average EV/EBIT ratio for DaVita Inc. (DVA)?
- The 20Y average EV/EBIT ratio for DVA stock is 12.70x.
DaVita Inc. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-12 | 12.94x |
| 2026-06-11 | 12.78x |
| 2026-06-10 | 12.60x |
| 2026-06-09 | 12.59x |
| 2026-06-08 | 12.39x |
| 2026-06-05 | 12.39x |
| 2026-06-04 | 12.39x |
| 2026-06-03 | 12.48x |
| 2026-06-02 | 12.25x |
| 2026-06-01 | 12.31x |
| 2026-05-29 | 12.46x |
| 2026-05-28 | 12.55x |
| 2026-05-27 | 12.48x |
| 2026-05-26 | 12.50x |
| 2026-05-22 | 12.60x |
| 2026-05-21 | 12.61x |
| 2026-05-20 | 12.55x |
| 2026-05-19 | 12.47x |
| 2026-05-18 | 12.63x |
| 2026-05-15 | 12.64x |
| 2026-05-14 | 12.40x |
| 2026-05-13 | 12.59x |
| 2026-05-12 | 12.67x |
| 2026-05-11 | 12.61x |
| 2026-05-08 | 12.60x |
| 2026-05-07 | 12.53x |
| 2026-05-06 | 12.45x |
| 2026-05-05 | 11.22x |
| 2026-05-04 | 13.70x |
| 2026-05-01 | 13.60x |
| 2026-04-30 | 13.75x |
| 2026-04-29 | 13.61x |
| 2026-04-28 | 13.53x |
| 2026-04-27 | 13.53x |
| 2026-04-24 | 13.61x |
| 2026-04-23 | 13.74x |
| 2026-04-22 | 13.63x |
| 2026-04-21 | 13.52x |
| 2026-04-20 | 13.50x |
| 2026-04-17 | 13.43x |
| 2026-04-16 | 13.44x |
| 2026-04-15 | 13.29x |
| 2026-04-14 | 13.50x |
| 2026-04-13 | 13.59x |
| 2026-04-10 | 13.53x |
| 2026-04-09 | 13.55x |
| 2026-04-08 | 13.46x |
| 2026-04-07 | 13.51x |
| 2026-04-06 | 13.53x |
| 2026-04-02 | 13.33x |
| 2026-04-01 | 13.54x |
| 2026-03-31 | 13.69x |
| 2026-03-30 | 13.63x |
| 2026-03-27 | 13.72x |
| 2026-03-26 | 13.82x |
| 2026-03-25 | 13.75x |
| 2026-03-24 | 13.67x |
| 2026-03-23 | 13.62x |
| 2026-03-20 | 13.50x |
| 2026-03-19 | 13.51x |
| 2026-03-18 | 13.47x |
| 2026-03-17 | 13.52x |
| 2026-03-16 | 13.45x |
| 2026-03-13 | 13.56x |
| 2026-03-12 | 13.66x |
| 2026-03-11 | 13.73x |
| 2026-03-10 | 13.59x |
| 2026-03-09 | 13.64x |
| 2026-03-06 | 13.56x |
| 2026-03-05 | 13.52x |
| 2026-03-04 | 13.73x |
| 2026-03-03 | 13.62x |
| 2026-03-02 | 13.70x |
| 2026-02-27 | 13.80x |
| 2026-02-26 | 13.64x |
| 2026-02-25 | 13.50x |
| 2026-02-24 | 13.56x |
| 2026-02-23 | 13.58x |
| 2026-02-20 | 13.56x |
| 2026-02-19 | 13.41x |
| 2026-02-18 | 13.43x |
| 2026-02-17 | 13.54x |
| 2026-02-13 | 13.48x |
| 2026-02-12 | 13.52x |
| 2026-02-11 | 13.28x |
| 2026-02-10 | 11.94x |
| 2026-02-09 | 11.88x |
| 2026-02-06 | 11.99x |
| 2026-02-05 | 12.30x |
| 2026-02-04 | 12.04x |
| 2026-02-03 | 11.77x |
| 2026-02-02 | 10.93x |
| 2026-01-30 | 10.86x |
| 2026-01-29 | 10.78x |
| 2026-01-28 | 10.73x |
| 2026-01-27 | 10.72x |
| 2026-01-26 | 10.79x |
| 2026-01-23 | 10.81x |
| 2026-01-22 | 10.85x |
| 2026-01-21 | 10.75x |
| 2026-01-20 | 10.66x |
| 2026-01-16 | 10.69x |
| 2026-01-15 | 10.73x |
| 2026-01-14 | 10.66x |
| 2026-01-13 | 10.68x |
| 2026-01-12 | 10.89x |
| 2026-01-09 | 10.93x |
| 2026-01-08 | 10.98x |
| 2026-01-07 | 10.92x |
| 2026-01-06 | 11.05x |
| 2026-01-05 | 11.02x |
| 2026-01-02 | 11.05x |
| 2025-12-31 | 11.01x |
| 2025-12-30 | 11.02x |
| 2025-12-29 | 11.01x |
| 2025-12-26 | 11.03x |
| 2025-12-24 | 11.04x |
| 2025-12-23 | 11.05x |
| 2025-12-22 | 11.12x |
| 2025-12-19 | 11.07x |
| 2025-12-18 | 11.10x |
| 2025-12-17 | 11.19x |
| 2025-12-16 | 11.17x |
| 2025-12-15 | 11.24x |
| 2025-12-12 | 11.29x |
| 2025-12-11 | 11.25x |
| 2025-12-10 | 11.20x |
| 2025-12-09 | 11.12x |
| 2025-12-08 | 11.14x |
| 2025-12-05 | 11.15x |
| 2025-12-04 | 11.14x |
| 2025-12-03 | 11.18x |
| 2025-12-02 | 11.21x |
| 2025-12-01 | 11.22x |
| 2025-11-28 | 11.23x |
| 2025-11-26 | 11.25x |
| 2025-11-25 | 11.29x |
| 2025-11-24 | 11.22x |
| 2025-11-21 | 11.25x |
| 2025-11-20 | 11.08x |
| 2025-11-19 | 11.07x |
| 2025-11-18 | 11.12x |
| 2025-11-17 | 11.14x |
| 2025-11-14 | 11.30x |
| 2025-11-13 | 11.35x |
| 2025-11-12 | 11.37x |
| 2025-11-11 | 11.32x |
| 2025-11-10 | 11.25x |
| 2025-11-07 | 11.38x |
| 2025-11-06 | 11.30x |
| 2025-11-05 | 11.28x |
| 2025-11-04 | 11.24x |
| 2025-11-03 | 11.21x |
| 2025-10-31 | 11.21x |
| 2025-10-30 | 11.20x |
| 2025-10-29 | 11.48x |
| 2025-10-28 | 10.66x |
| 2025-10-27 | 10.65x |
| 2025-10-24 | 10.64x |
| 2025-10-23 | 10.60x |
| 2025-10-22 | 10.64x |
| 2025-10-21 | 10.61x |
| 2025-10-20 | 10.60x |
| 2025-10-17 | 10.52x |
| 2025-10-16 | 10.49x |
| 2025-10-15 | 10.52x |
| 2025-10-14 | 10.55x |
| 2025-10-13 | 10.44x |
| 2025-10-10 | 10.45x |
| 2025-10-09 | 10.54x |
| 2025-10-08 | 10.59x |
| 2025-10-07 | 10.71x |
| 2025-10-06 | 10.60x |
| 2025-10-03 | 10.71x |
| 2025-10-02 | 10.75x |
| 2025-10-01 | 10.78x |
| 2025-09-30 | 10.78x |
| 2025-09-29 | 10.69x |
| 2025-09-26 | 10.70x |
| 2025-09-25 | 10.68x |
| 2025-09-24 | 10.81x |
| 2025-09-23 | 10.78x |
| 2025-09-22 | 10.71x |
| 2025-09-19 | 10.68x |
| 2025-09-18 | 10.68x |
| 2025-09-17 | 10.60x |
| 2025-09-16 | 10.68x |
| 2025-09-15 | 10.71x |
| 2025-09-12 | 10.79x |
| 2025-09-11 | 10.79x |
| 2025-09-10 | 10.76x |
| 2025-09-09 | 10.92x |
| 2025-09-08 | 10.84x |
| 2025-09-05 | 10.96x |
| 2025-09-04 | 10.88x |
| 2025-09-03 | 10.89x |
| 2025-09-02 | 10.93x |
| 2025-08-29 | 10.96x |
| 2025-08-28 | 10.90x |
| 2025-08-27 | 10.95x |
| 2025-08-26 | 10.99x |
| 2025-08-25 | 10.94x |
| 2025-08-22 | 11.06x |
| 2025-08-21 | 10.95x |
| 2025-08-20 | 10.95x |
| 2025-08-19 | 10.92x |
| 2025-08-18 | 10.79x |
| 2025-08-15 | 10.87x |
| 2025-08-14 | 10.83x |
| 2025-08-13 | 10.85x |
| 2025-08-12 | 10.75x |
| 2025-08-11 | 10.64x |
| 2025-08-08 | 10.65x |
| 2025-08-07 | 10.59x |
| 2025-08-06 | 10.59x |
| 2025-08-05 | 11.06x |
| 2025-08-04 | 11.35x |
| 2025-08-01 | 11.31x |
| 2025-07-31 | 11.39x |
| 2025-07-30 | 11.55x |
| 2025-07-29 | 11.61x |
| 2025-07-28 | 11.58x |
| 2025-07-25 | 11.58x |
| 2025-07-24 | 11.56x |
| 2025-07-23 | 11.82x |
| 2025-07-22 | 11.61x |
| 2025-07-21 | 11.35x |
| 2025-07-18 | 11.42x |
| 2025-07-17 | 11.51x |
| 2025-07-16 | 11.38x |
| 2025-07-15 | 11.39x |
| 2025-07-14 | 11.51x |
| 2025-07-11 | 11.47x |
| 2025-07-10 | 11.51x |
| 2025-07-09 | 11.44x |
| 2025-07-08 | 11.52x |
| 2025-07-07 | 11.48x |
| 2025-07-03 | 11.47x |
| 2025-07-02 | 11.47x |
| 2025-07-01 | 11.64x |
| 2025-06-30 | 11.47x |
| 2025-06-27 | 11.44x |
| 2025-06-26 | 11.41x |
| 2025-06-25 | 11.39x |
| 2025-06-24 | 11.41x |
| 2025-06-23 | 11.23x |
| 2025-06-20 | 11.25x |
| 2025-06-18 | 11.20x |
| 2025-06-17 | 11.23x |
| 2025-06-16 | 11.29x |
| 2025-06-13 | 11.22x |
| 2025-06-12 | 11.27x |
| 2025-06-11 | 11.30x |
| 2025-06-10 | 11.34x |
| 2025-06-09 | 11.28x |
| 2025-06-06 | 11.29x |
| 2025-06-05 | 11.28x |
| 2025-06-04 | 11.24x |
| 2025-06-03 | 11.21x |
| 2025-06-02 | 11.15x |
Showing the most recent 260 of 5,033 data points. The chart above shows the full history.
Related Metrics
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Javier J. Rodriguez